Skip to main
INSP

INSP Stock Forecast & Price Target

INSP Analyst Ratings

Based on 17 analyst ratings
Buy
Strong Buy 12%
Buy 35%
Hold 53%
Sell 0%
Strong Sell 0%

Bulls say

Inspire Medical Systems has demonstrated substantial growth, as indicated by its increase in employee count to 1,333 in 2025 from 1,246 in 2024, reflecting an expanding operational capacity. The company's strategic focus on marketing is evidenced by a significant 21% increase in advertising expenses, reaching $114.9 million in 2025, suggesting an aggressive approach to drive sales and market penetration. Furthermore, the expected return to double-digit sales growth in the global hypoglossal nerve stimulation (HGNS) market, along with projected profitability improvements in 2026, supports a favorable outlook for the firm's financial performance.

Bears say

Inspire Medical Systems Inc. has lowered its revenue guidance for fiscal year 2026 from a range of $1,003-1,013 million to $950-1,000 million, reflecting anticipated challenges related to reimbursement and coding uncertainties. The company is facing significant headwinds, particularly due to a deceleration in domestic growth and the potential disincentives for ENT specialists to perform necessary procedures in light of evolving reimbursement frameworks. As uncertainty persists regarding the company's near-term growth outlook, it is suggested that a lower valuation multiple is warranted to account for these challenges.

INSP has been analyzed by 17 analysts, with a consensus rating of Buy. 12% of analysts recommend a Strong Buy, 35% recommend Buy, 53% suggest Holding, 0% advise Selling, and 0% predict a Strong Sell.

This aggregate rating is based on analysts' research of Inspire Medical Systems Inc and is not a guaranteed prediction by Public.com or investment advice.

Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy

FAQs About Inspire Medical Systems Inc (INSP) Forecast

Analysts have given INSP a Buy based on their latest research and market trends.

According to 17 analysts, INSP has a Buy consensus rating as of Apr 23, 2026. This rating is provided by third-party analysts and is not investment advice from Public.com.

Wall Street analysts have set a price target of $103.94, reflecting a 0.00% increase from the current stock price.

Financial analysts have set a price target of $103.94, indicating a 0.00% increase from the current stock price, but ratings and forecasts are frequently updated based on market conditions, earnings reports, and industry trends. This prediction is provided by third-party analysts and is not investment advice from Public.com.

Inspire Medical Systems Inc (INSP)


Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy
Disclaimer: Any investment listed here, which may be available on the Public platform, is intended to be used for informational purposes only, should not be the sole basis for making an investment decision, and is not a recommendation or advice.